Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
d4T fat wasting risk rises with baseline triglycerides

The risk of developing lipoatrophy (fat wasting) during treatment with d4T (stavudine, Zerit) appears to be highest in individuals with high baseline triglyceride levels, in

Published
20 February 2004
By
Edwin J. Bernard
Expensive micronutrient formula associated with CD4 increases

A broad-spectrum micronutrient formula developed by a California HIV practitioner has been shown to significantly increase CD4 cell counts - by 25% over 12 weeks

Published
20 February 2004
By
Edwin J. Bernard
HIV attachment inhibitors: three more join the ranks at CROI

Three companies presented promising data on drugs which block the entry of HIV into cells at last week's Eleventh Conference on Retroviruses and Opportunistic Infections

Published
18 February 2004
By
Keith Alcorn
Diabetes and high glucose levels more common in HIV-positive men on HAART

HIV-infected men using antiretroviral therapy have higher rates of hyperglycaemia (high blood glucose) and diabetes compared with HIV-negative men, according to an American study presented

Published
18 February 2004
By
Liz Highleyman
South Africa’s antiretroviral rollout stalled

Delays in the drug procurement process and lack of training for doctors are postponing the rollout of antiretroviral therapy (ART) in South Africa, the country’s

Published
16 February 2004
By
Theo Smart
NNRTI-based HAART effective and safe for primary HIV infection

A HAART regimen based on the non-nucleoside (NNRTI) efavirenz is a virologically and immunologically effective and safe treatment for primary HIV infection, according to a

Published
13 February 2004
By
Michael Carter
FTC has potent anti-HBV effect in HIV/HBV coinfected patients, and rate of resistance low

FTC (emtricitabine, Emtriva) has potent anti-hepatitis B virus (HBV) and anti-HIV activity when included in the HAART regimens of individuals coinfected with HBV and HIV,

Published
12 February 2004
By
Michael Carter
Transmission of drug-resistant HIV: what are the implications for treatment?

Although drug resistance may linger for months or even years when individuals become infected with a drug resistant virus, evidence from a large European study

Published
12 February 2004
By
Keith Alcorn
Vaccine research: back to the drawing board?

The major presentations on HIV vaccines at the Eleventh Conference on Retroviruses and Opportunistic Infections in San Francisco were dominated by one question. Is it

Published
12 February 2004
By
Julian Meldrum
Doctors rebellion against ritonavir price increase spreads in US

Despite concessions announced last Friday by Abbott Laboratories, anger among US doctors over the company’s decision to quadruple the price of its protease inhibitor Norvir

Published
11 February 2004
By
Keith Alcorn

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.